Published in final edited form as:

J Clin Cell Immunol. 2014 December ; 5(6): . doi:10.4172/2155-9899.1000e114.

The Human Microbiome and the Immune System: An Ever Evolving Understanding

Vanessa Rivera-Amill, Ph.D.

Department of Microbiology and RCMI AIDS Program, Ponce Health Sciences University-School of Medicine/ Ponce Research Institute, 395 Research Building Zona Industrial Reparada 2, Ponce PR 00716-2347

The human body is home to bacteria, archaea, fungi, viruses, protists, and microscopic animals, all of which comprise the microbiome—all the microbes that “share our body space” [1]. The definition of what makes us *human* needs to account for the traits provided by these microorganisms as well as for the fact that we did not have to evolve on our own [2]. Work on the Human Genome Project [3] led to the realization that decoding the human genome would not provide the full picture for understanding human biology, as the microbial communities in/on our bodies by far exceed our own cells in number and gene content [4].

What are the roles of all of the microbes and microbial genes in our bodies? The microbes benefit from a stable habitat—rich in energy sources from the food we ingest—and we in turn claim heat energy from otherwise indigestible compounds such as cellulose. But the interaction between the microbes and their human host is far reaching. The microbiota present at each body site affects numerous biological functions important for maintaining health, whereas the alteration of the microbiota components (dysbiosis) can contribute to disease development. Given the complexity of the human microbiome, identifying and/or interpreting dysbiosis is not trivial. The study of the microbiome is a rapidly evolving area of interest, and a great deal of effort has been invested in understanding the microbial makeup of a healthy individual, that is, to determining what types of microbes are present, and finding out what are they doing. The International Human Microbiome Consortium (IHMC) was constituted in 2005 in order to begin to understand how microbes influence human health and disease [5]. The National Institutes of Health (NIH) joined this international effort by launching the Human Microbiome Project (HMP), an initiative of the NIH Roadmap for Biomedical Research (<http://nihroadmap.nih.gov>) to examine the normal microbial composition in 4 body sites: the gastrointestinal tract, the mouth, the vagina, and the skin [5, 6]. The goals of the HMP are three-fold: 1., to characterize the human microbiome from normal volunteers by using high-throughput technologies; 2., to study several different conditions to determine whether there are associations between changes in the microbiome and health/disease; and 3., to provide a standardized data resource and new technological approaches that can be used by the scientific community. All of the data generated from this effort have been used to define a core microbiome at each body site,

denoting the existence of highly specialized niches and interactions between the microbiome and the human tissues [7, 8]. An obvious interaction is that of the microbiota with the components of the immune system, both innate and adaptive. The immune system refers to the tissues, cells, and molecules that protect the body against infectious agents. What then determines which microbiota colonizes a particular body site and, in turn, how the microorganisms making up the microbiota help shape our immune system?

The gastrointestinal tract comprises the largest and most complex population of microorganisms, as well as the largest mass of lymphoid tissue, in the body, the gut-associated lymphoid tissue (GALT)—the first line of defense for the intestinal mucosa. As the cellular components of the immune system come into contact with a microorganism, they are faced with assessing whether or not a particular microorganism is beneficial or pathogenic. In addition, the composition of the microbiota itself exerts a reciprocal effect on the immune system. For example, treating animals with different antibiotics often results in the altering of their microbiota profiles, leading to different responses to bacterial infections [9]. On the other hand, the composition of the gut microbiota may also impact the bioavailability and metabolism of the drugs leading to altered disease outcomes [10]. A key experimental advance for unraveling the crosstalk between the microorganisms and their host was the development of gnotobiotic (germ-free, GF) animals [11, 12]. The availability of GF animals (no bacteria in the intestine or on other body surfaces) provided important insights into how the microbiota shapes the host immune system. Early studies in the 1960s demonstrated that the cellular and serologic responses in GF mice were slightly delayed and of decreased magnitude and that their macrophages exhibited a decreased digestive capacity as compared to that of conventional mice [13, 14]. In terms of the development of the GALT, GF mice display morphological changes resulting from the lack of microbial colonization; compared to mice with microbiota, GF mice have fewer and smaller Peyer's patches, smaller and fewer mesenteric lymph nodes (MLNs), and fewer cellular lamina propria of the small intestine [15, 16]. GF animals can be used in the examination of the phenomenon of microbiota colonization and to define the underlying mechanisms of that phenomenon. The gut microbiota provides not only pathogen colonization resistance but also plays a role in immune system-mediated responses. Studies in GF animals have provided evidence of the importance of the gut microbiota in the development a wide range of pathologies. A partial list includes, graft-versus-host disease (GVHD) [17], certain pathologic states resembling both human inflammatory bowel disease (IBD) and ankylosing spondylitis [18–20], colorectal tumorigenesis [21–23], the resistance of the eye to infection [24], obesity [25], and the hypothalamic–pituitary–adrenal axis (HPA) stress response [26], among others. To assess the underlying mechanisms of the human gut microbiota in the development of all of these conditions as well as others, human fecal microbial communities have been transplanted into GF mice using a validated procedure [27]. These *humanized fecal microbiota mice* are instrumental for conducting proof-of-principle trials for examining the balance of the gut microbiota and the host physiology in the context of environmental and genetic factors. Although not a new therapeutic intervention fecal microbiota transplantation (FMT)—the infusion of a suspension of fecal matter from a healthy individual into the gastrointestinal tract (GI) of a diseased individual—has received much public attention in the treatment and cure of specific diseases. For example, several studies have shown that

FMT provides its therapeutic benefit by re-establishing a balanced microbiota in patients with recurrent *Clostridium difficile* infection (RCDI) [28, 29]. To date all the studies have reported remarkable cure rates (>90%) without serious adverse events directly attributable to FMT [30, 31]. Benefits of FMT included the restoration of the colonic microbiota to its natural state by replacing missing *Bacteroidetes* and *Firmicutes* species and the resolution of clinical symptoms such as diarrhea, cramping, and urgency [30, 31]. Other GI disorders in which FMT has been successfully used include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). In the United States, an underestimated 1 to 1.2 million individuals suffer from IBD in a roughly similar distribution between Crohn's disease (CD) and ulcerative colitis (UC) [32].

In the previous issue of this journal, Jin et al. discussed the role of the host–microbe interactions in the development of IBD and the manipulation of the gut microbiota as a clinical therapeutic strategy [33]. Although the etiology of IBD is incompletely understood, a number of contributing factors were discussed, including the role of the microbiome balance (bacteria, viruses, bacteriophages, and fungi) and pathogenic bacteria [33]. An important aspect that also needs to be accounted for is the nature of the microbial and the immune system response interaction during the transition from physiological to tissue-damaging intestinal inflammation that manifests in IBD patients [34]. A recent meta-analysis of FMT as a therapy for inflammatory bowel disease suggests that FMT is generally tolerable and safe [35]. According to the 18 studies (cohort and case) to date that have examined FMT as a primary and adjunctive therapy for IBD, 45% of the patients who participated achieved clinical remission [35]. The lower percentage of clinical remission in FMT-treated patients who had IBD compared to those with RCDI may reflect the complex nature of IBD, and indicates that there is much still to be learned. This observation underlines the importance of understanding the human microbiome, in that doing so should lead to the discovery of disease triggers, novel targets and mechanisms, novel disease interception strategies, and new drugs and diagnostic methods. Currently available modulators of the microbial ecosystem include FMT (described above), prebiotics, probiotics, and antibiotics. However, more refined modulators, such as genetically modified *Lactobacillus*, are being bioengineered offering novel approaches to the prevention and treatment of diseases [36, 37].

A look to the near future reveals a number of needs and opportunities. Clearly defining the underlying microbiome–immune system pathways regulating both health and disease processes is important in terms of designing new intervention and therapeutic strategies with improved relevance and efficacy. Advances in sequencing technologies and the development of new tools have let us begin to uncover the dynamics of the microbiome. We must therefore make the most of the renewed interest in the microbiome, which clearly highlights the interests of researchers at many institutions around the world who are teaming up to address the underlying mechanisms of our co-existence with the microbial world.

Acknowledgments

The author would like to acknowledge the editing services of Mr. Bob Ritchie, Ponce Health Sciences University. The project was supported by the National Institutes of Health, NIMHD (G12-MD007579).

References

1. Lederberg J, McCray A. The Scientist : 'Ome Sweet 'Omics-- A Genealogical Treasury of Words. The Scientist. 2001; 17
2. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006; 312:1355–1359. [PubMed: 16741115]
3. International consortium completes human genome project. Pharmacogenomics. 2003; 4:241. [PubMed: 12718714]
4. Davies J. In a map for human life, count the microbes, too. Science. 2001; 291:2316. [PubMed: 11269298]
5. Group NHW, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. The NIH Human Microbiome Project. Genome research. 2009; 19:2317–2323. [PubMed: 19819907]
6. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007; 449:804–810. [PubMed: 17943116]
7. Grice EA, Segre JA. The human microbiome: our second genome. Annual review of genomics and human genetics. 2012; 13:151–170.
8. Song S, Jarvie T, Hattori M. Our second genome-human metagenome: how next-generation sequencer changes our life through microbiology. Advances in microbial physiology. 2013; 62:119–144. [PubMed: 23481336]
9. Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y, Lupp C, Finlay BB. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infection and immunity. 2008; 76:4726–4736. [PubMed: 18678663]
10. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nature reviews. Drug discovery. 2008; 7:123–129.
11. Heinecke H. The origins of the gnotobiotic technic--Kuster/Nuttall/Schottelius/Thierfelder. Zeitschrift fur Versuchstierkunde. 1990; 33:19–22. [PubMed: 2181795]
12. Gustafsson B. Germ-free rearing of rats. Acta anatomica. 1946; 2:376–391. [PubMed: 20256962]
13. Bauer H, Paronetto F, Burns WA, Einheber A. The enhancing effect of the microbial flora on macrophage function and the immune response. A study in germfree mice. The Journal of experimental medicine. 1966; 123:1013–1024. [PubMed: 5328828]
14. Olson GB, Wostmann BS. Cellular and humoral immune response of germfree mice stimulated with 7S HGG or Salmonella typhimurium. Journal of immunology. 1966; 97:275–286.
15. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiology and molecular biology reviews : MMBR. 1998; 62:1157–1170. [PubMed: 9841668]
16. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nature reviews. Immunology. 2004; 4:478–485.
17. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. Journal of medicine. 1992; 23:161–173. [PubMed: 1479298]
18. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of experimental medicine. 1994; 180:2359–2364. [PubMed: 7964509]
19. Bjork J, Kleinau S, Midtvedt T, Klareskog L, Smedegard G. Role of the bowel flora for development of immunity to hsp 65 and arthritis in three experimental models. Scandinavian journal of immunology. 1994; 40:648–652. [PubMed: 7997855]

20. Kohashi O, Kohashi Y, Takahashi T, Ozawa A, Shigematsu N. Suppressive effect of *Escherichia coli* on adjuvant-induced arthritis in germ-free rats. *Arthritis and rheumatism*. 1986; 29:547–553. [PubMed: 3518723]
21. Gorbach SL, Goldin BR. The intestinal microflora and the colon cancer connection. *Reviews of infectious diseases*. 1990; 12(Suppl 2):S252–S261. [PubMed: 2154844]
22. Midtvedt T. Germfree Animals and Carcinogenesis. *Bioscience and Microflora*. 1997; 16:9–11.
23. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. The gut microbiome modulates colon tumorigenesis. *mBio*. 2013; 4:e00692-13. [PubMed: 24194538]
24. Zaidi T, Zaidi T, Cywes-Bentley C, Lu R, Priebe GP, Pier GB. Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to *Staphylococcus aureus* infection in the eye. *Infection and immunity*. 2014; 82:3483–3491. [PubMed: 24914214]
25. Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. *The ISME journal*. 2013; 7:880–884. [PubMed: 23235292]
26. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *The Journal of physiology*. 2004; 558:263–275. [PubMed: 15133062]
27. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Science translational medicine*. 2009; 1:6ra14.
28. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent *Clostridium difficile*-associated diarrhea. *Journal of clinical gastroenterology*. 2010; 44:354–360. [PubMed: 20048681]
29. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *The American journal of gastroenterology*. 2013; 108:500–508. [PubMed: 23511459]
30. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. *Gastrointestinal endoscopy*. 2013; 78:240–249. [PubMed: 23642791]
31. Austin M, Mellow M, Tierney WM. Fecal microbiota transplantation in the treatment of *Clostridium difficile* infections. *The American journal of medicine*. 2014; 127:479–483. [PubMed: 24582877]
32. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. *Digestive diseases and sciences*. 2013; 58:519–525. [PubMed: 22926499]
33. Jin D, Zhang H, Sun J. Manipulation of Microbiome, a Promising Therapy for Inflammatory Bowel Diseases. *Journal of Clinical and Cellular Immunology*. 2014; 5
34. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*. 2007; 448:427–434. [PubMed: 17653185]
35. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. *Journal of Crohn's & colitis*. 2014
36. Gunaydin G, Alvarez B, Lin Y, Hammarstrom L, Marcotte H. Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in *Lactobacillus*: development and functionality of vectors containing two expression cassettes in tandem. *PloS one*. 2014; 9:e96409. [PubMed: 24781086]
37. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, Lee PP, Hamer DH. Prevention of vaginal SHIV transmission in macaques by a live recombinant *Lactobacillus*. *Mucosal immunology*. 2011; 4:648–657. [PubMed: 21734653]